Efficacy and safety of intracoronary recombinant human pro-urokinase or Tirofiban injection during primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction:a Meta analysis
Efficacy and safety of intracoronary recombinant human pro-urokinase or Tirofiban injection during primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction:a Meta analysis
Objective Intracoronary administration of Tirofiban or recombinant human pro-urokinase(rhPro-UK)during primary percutaneous coronary intervention(PPCI)has been shown to improve coronary artery microcirculation perfusion.This study aims to explore the efficacy and safety of intracoronary rhPro-UK or Tirofiban in patients with ST-segment elevation myocardial infarction(STEMI)undergoing PPCI.Methods The PubMed,Ovid-MEDLINE,Embase,Web of Science,Cochrane Library,clinical trials.gov,CNKI,WANFANG,VIP,SinoMed,databases were searched for randomized controlled trials(RCTs)or cohort researches of the Intracoronary injection of rhPro-UK or Tirofiban during PPCI in STEMI patients from inception to 27th November 2023.Two reviewers independently screened literature,extracted data and assessed the risk of bias of included studies.Meta-analysis of data was performed by RevMan 5.4.Results There were 12 studies involving 1 721 patients were included,with 864 in the rhPro-UK group(experimental group)and 857 in the Tirofiban group(control group).Meta-analysis showed that compared to the control group,intracoronary rhPro-UK significantly improved postoperative myocardial blood flow perfusion,including higher proportions of thrombolysis in myocardial infarction(TIMI)grade Ⅲ and TIMI myocardial perfusion grades(TMPG)grade Ⅲ(OR 1.83,95％CI 1.36-2.46,P＜0.0001;OR 2.38.95％CI 1.22-4.66,P=0.010);And significantly lower corrected T1M1 frame count(cTFC)(MD-2.43,95％CI-2.94--1.92,P＜0.00001);ST-segment resolution(STR)≥70％was higher than that of control group(OR 1.93,95％CI 1.01-3.68,P=0.050).There was a significant reduction in major adverse cardiovascular events(MACE)one month postoperatively(OR 0.54,95％CI 0.35-0.82,P=0.004).Improving cardiac function one month after surgery,higher left ventricular ejection fraction(LVEF)(MD 1.71,95％CI 0.04-3.38,P=0.050).Reducing the size of the myocardial infarction,the postoperative peak value of CK-MB was lower than that of control group(MD-74.16,95％CI-83.59--64.74,P＜0.00001).The incidence of bleeding event was not significantly different between groups(OR 1.18,95％CI 0.64-2.16,P=0.600).Conclusions In STEMI patients undergoing PPCI,intracoronary rhPro-UK improves coronary artery microcirculation perfusion and cardiac function more effectively than Tirofiban,reducing the size of the myocardial infarction and the occurrence of MACE after PPCI 1 month,and there was no significant difference in bleeding events between the two groups.
关键词
ST段抬高型心肌梗死/重组人尿激酶原/替罗非班/直接经皮冠状动脉介入治疗/Meta分析
Key words
ST-segment elevation myocardial infarction/Recombinant human pro-urokinase/Tirofiban/Direct percutaneous coronary intervention/Meta-analysis
维普
万方数据